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Although liposarcoma is the most common sarcoma in adults,only 15 pleural liposarcomas have been reported.1,2 We
present a giant pleural liposarcoma treated with induction che-
motherapy and surgical resection.
Clinical Summary
A 38-year-old man with no medical or smoking his-
tory presented with cough, night sweats, and intermittent
chest pain. Computed tomography (CT) demonstrated a
heterogeneous mass involving most of the right and ex-
tending into the left hemithorax (Figure 1A). Thoraco-
scopic biopsy showed myxoid liposarcoma (Figure 2A).
Positron emission tomography/CT scan after three courses
of ifosfamide (2 g/m2 over 96 hours) and adriamycin (25
mg/m2 over 72 hours) administered every 3 weeks showed
no change in mass size but decrease in fluorodeoxyglucose
activity from maximal standardized-uptake-value of 4.8 mid-
therapy to 3.3 posttherapy. A 4258 g, 29.3  25.8  14.1 cm
tumor (Figure 1B) that originated from middle mediastinal
pleura without direct involvement of lung, pericardium, or
esophagus was resected via right thoracotomy. The mass
had vascular branches from the aorta and the azygos
venous system and was removed with sparing of all other
structures by circumferential dissection. Microscopic ex-
amination showed a thinly encapsulated high grade myx-
oid liposarcoma with approximately 10% residual viable
tumor and no histologically viable sarcoma at the margins
(Figure 2B). The patient underwent redo thoracotomy and
thoracic duct ligation on postoperative day 2 to repair a
chylothorax and was discharged 5 days later. Six weeks
postsurgery, the patient received two additional cycles of
ifosfamide and adriamycin at the same preoperative dose
and schedule. A positron emission tomography/CT 16 months
postsurgery shows no disease (Figure 3).
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FIGURE 1. A, Pretreatment computed tomography scan. B,
Resected liposarcoma.
Journal of Thoracic Oncology • Volume 4, Number 6, June 2009768
DISCUSSION
Intrathoracic sarcomas are uncommon. Mediastinal sar-
comas represent 1.4% of the 6000 soft tissue sarcomas seen
in the United States yearly.3 Liposarcomas of the pleural
cavity are more rare, with 15 cases reported.1 These tumors
cause vague symptoms and can enlarge significantly.2 The
resected tumor in this report weighed 4.26 kg, slightly smaller
than the largest reported size of 4.46 kg.2
Resection is the optimal treatment. The role of adjuvant
therapy is hard to define due to the tumor rarity. Although
only 2 of the 15 previously reported cases of pleural liposar-
coma involved adjuvant chemotherapy, induction chemother-
apy should be considered to maximize the chance for com-
plete resection.1 Although debulking can reduce symptoms,
the overwhelming factor determining survival for mediastinal
sarcomas is complete resection.3 In this case, induction che-
motherapy followed by surgery resulted in a complete resection
(R0), which will hopefully optimize the patient’s survival.
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FIGURE 2. A, Pretreatment biopsy showing myxoid liposar-
coma. B, Posttreatment histology showing sclerosis and min-
imal cellularity.
FIGURE 3. Postoperative scan showing no residual or re-
current disease.
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